New personalized immune combo aims to stop colorectal cancer from coming back

This early-phase study tests whether adding a personalized immune treatment to standard chemotherapy can prevent cancer from returning in colorectal cancer patients who have signs of remaining cancer cells (MRD-positive) after surgery. Ten adults aged 18-80 with stage II (high-risk) or stage III colorectal cancer will receive a custom-made immune modulator based on their tumor's unique features. The goal is to see if this approach improves response rates and delays or prevents recurrence.